STOCK TITAN

Nurix Therapeutics, Inc. - NRIX STOCK NEWS

Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.

Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.

Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.

In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.

Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) has received FDA clearance for its IND application to expand the Phase 1 clinical trial of NX-5948, a BTK degrader, into the U.S. Following successful initial trials in the UK, the company will begin enrolling patients with relapsed and refractory B-cell malignancies in the U.S. in 2023. NX-5948 has demonstrated potent BTK degradation, potentially offering a new treatment option for patients. The trial aims to assess the safety and tolerability of this investigational drug, which is designed to lack certain immunomodulatory activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
none
-
Rhea-AI Summary

Nurix Therapeutics (NRIX) reported promising results from its Phase 1 trial of NX-2127, a treatment for chronic lymphocytic leukemia (CLL) at the ASH Annual Meeting. The trial included 36 adults, with 23 being heavily pretreated CLL patients. NX-2127 demonstrated a 33% overall response rate and effective BTK degradation, regardless of previous treatments or BTK mutations. The safety profile was consistent with existing BTK therapies. The company continues to explore NX-2127's potential while preparing for further clinical updates in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
-
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) has announced a live webcast on December 12, 2022, at 8:30 PM CT to review clinical data from the Phase 1 trial of its BTK degrader program, NX-2127. The event will feature insights from Dr. Anthony Mato, focusing on chronic lymphocytic leukemia patients. NX-2127 targets Bruton’s tyrosine kinase and is currently being evaluated in patients with relapsed or refractory B-cell malignancies. The ongoing study is registered under NCT04830137.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
Rhea-AI Summary

Nurix Therapeutics presented promising preclinical data for its CBL-B inhibitor NX-0255 at the 37th Annual Meeting of the SITC. This data suggests that NX-0255 can enhance T-cell therapy in the DeTIL-0255 program aimed at treating gynecologic malignancies. The ongoing Phase 1 trial has completed its safety run-in with positive outcomes in patients. Furthermore, FDA feedback supports the combination of NX-0255 with DeTIL-0255, indicating potential for future trial expansions. Nurix plans to advance the development of its CBL-B inhibitors in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.42%
Tags
-
Rhea-AI Summary

Nurix Therapeutics (NRIX) presented initial biomarker data from its Phase 1 trial of NX-1607, an innovative CBL-B inhibitor, at the SITC Annual Meeting. The results show target engagement correlating to significant anti-tumor activity, with biomarker levels indicating dose-dependency. NX-1607 effectively activates T and NK cells, enhancing immune response in tumor settings. Preliminary findings suggest a mean half-life of 6 to 8 hours for NX-1607, reinforcing its potential as a key oncology therapy. Additional updates are anticipated in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.42%
Tags
-
Rhea-AI Summary

Nurix Therapeutics (NASDAQ: NRIX) announced a clinical update for its ongoing Phase 1 trial of NX-2127, a targeted protein degrader for patients with hematologic malignancies. The updates will be presented at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. Dr. Anthony Mato of Memorial Sloan Kettering Cancer Center will give an oral presentation on chronic lymphocytic leukemia (CLL) patients. NX-2127 degrades Bruton’s tyrosine kinase (BTK) and is currently under evaluation in clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical company focused on developing targeted protein modulation therapies for cancer, announced key participation in November conferences. CEO Arthur T. Sands will present at:

  • Credit Suisse 31st Annual Healthcare Conference on November 8, 11:25 - 11:55 a.m. ET.
  • Piper Sandler 34th Annual Healthcare Conference on November 30, 4:30 - 4:55 p.m. ET.

The events will be webcast and available on the company's website for about 30 days afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
-
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced promising initial results from the NX-2127 clinical trial for patients with diffuse large B cell lymphoma (DLBCL). A patient achieved a complete response at 8 weeks, confirmed at 16 weeks, after receiving 300 mg of NX-2127 daily. This dual-action drug targets Bruton’s tyrosine kinase (BTK) and aids in degrading key proteins linked to tumor proliferation. The NX-2127 trial shows potential for addressing unmet medical needs in aggressive lymphomas, with further updates expected at the upcoming American Society of Hematology meeting in December.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced plans to present at the 5th Annual TPD Summit from October 25-28, 2022, in Boston, MA. A Keynote Plenary will be delivered by Arthur T. Sands, M.D., Ph.D., the CEO, discussing advancements in BTK degraders for hematologic malignancies. Other presentations include topics on targeted protein degradation and orally active, brain-penetrant degraders. Nurix focuses on developing therapies that modulate cellular protein levels, utilizing their DELigase discovery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
none
Rhea-AI Summary

Nurix Therapeutics reported Q3 2022 results, highlighting a gross revenue of $10.8 million, up from $10.3 million in Q3 2021. The company raised $95 million from two registered direct offerings in July, bolstering its cash position to $413.6 million as of August 31, 2022. R&D expenses rose to $47.8 million, reflecting increased clinical activities, while net loss was $45.7 million or $0.90 per share. Nurix expanded its leadership team and announced six presentations at the SITC 2022 annual meeting, including initial data for its NX-1607 program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags

FAQ

What is the current stock price of Nurix Therapeutics (NRIX)?

The current stock price of Nurix Therapeutics (NRIX) is $22.05 as of November 22, 2024.

What is the market cap of Nurix Therapeutics (NRIX)?

The market cap of Nurix Therapeutics (NRIX) is approximately 1.6B.

What does Nurix Therapeutics, Inc. specialize in?

Nurix Therapeutics specializes in discovering, developing, and commercializing therapies that modulate cellular protein levels to treat cancer, inflammatory conditions, and other diseases.

What is the significance of Nurix's DELigase platform?

DELigase is Nurix's proprietary drug discovery platform that identifies and advances novel drug candidates targeting E3 ligases, crucial enzymes in protein regulation.

Who are Nurix's major partners?

Nurix has strategic collaborations with industry leaders like Celgene, Sanofi, Gilead, and Pfizer to develop next-generation therapies.

What are some of Nurix's key drug candidates?

Key drug candidates include NX-2127, an orally available BTK degrader for B-cell malignancies, and NX-1607, a CBL-B inhibitor for immuno-oncology.

How has Nurix performed financially in recent quarters?

Nurix reported increased revenue in the first quarter of 2024 due to collaborations and achieved research milestones, with substantial cash reserves supporting ongoing projects.

Where is Nurix Therapeutics headquartered?

Nurix Therapeutics is headquartered in San Francisco, California.

What recent leadership changes have occurred at Nurix?

Julia P. Gregory has been elected as the new board chair, succeeding Dr. David L. Lacey, who will continue to serve on the board and its committees.

What is the focus of Nurix's collaboration with Sanofi?

The collaboration with Sanofi focuses on developing targeted protein degraders for inflammatory conditions, including the STAT6 pathway.

What are Nurix's plans for NX-5948?

Nurix plans to continue clinical trials for NX-5948, a BTK degrader, and explore its use in treating B-cell malignancies with CNS involvement.

How can I learn more about Nurix Therapeutics?

For more information, visit Nurix's official website at http://www.nurixtx.com.

Nurix Therapeutics, Inc.

Nasdaq:NRIX

NRIX Rankings

NRIX Stock Data

1.58B
69.46M
1.45%
98.27%
13.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO